Korean biotech Mezzion Pharma blames Dr. Reddy’s Laboratories for the FDA’s rejection of its New Drug Application seeking approval of udenafil for the treatment of erectile dysfunction and intends to litigate to recover alleged damages. The company says RDY’s “misconduct” related to cGMP deficiencies was the sole reason for the failed submission.